{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:38:22Z","timestamp":1792165102813,"version":"4.4.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The treatment of obesity and type 2 diabetes (T2D) in Prader-Willi syndrome (PWS) is still a challenge. Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are attractive options, since they effectively reduce weight and improve blood glucose, without increasing the risk of hypoglycemia. However, data on their use in PWS are scarce.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>In 2019, a 27-year-old male came to our Clinic because of first appearance of severe hyperglycemia (fasting plasma glucose 22.5 mmol\/L). Based on clinical presentation, PWS was suspected, and diagnosis was confirmed by genetic tests. The patient was discharged on a basal-bolus insulin therapy managed by his parents due to his cognitive impairment. In spite of COVID-19 pandemic, the patient achieved tight glycemic control (HbA1c 41 mmol\/mol) with non-severe hypoglycemic events in the face of significant body weight (BW) increase (+ 13\u00a0kg vs baseline). Insulin therapy was then discontinued, and once-weekly semaglutide (up to 0,5 mg weekly) was started. At 12-month follow-up, BW dropped from 79 to 73\u00a0kg while maintaining excellent glycemic control (HbA1c 40 mmol\/mol). At 24-month follow-up, glycemic control remained optimal (HbA1c 38 mmol\/mol) with further BW reduction (71\u00a0kg). Neither hypoglycemia nor gastro-intestinal or psychiatric adverse events were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case supports the potential use of semaglutide for the treatment of subjects with PWS, obesity and T2D. <jats:italic>Ad hoc<\/jats:italic> trials are needed to evaluate the long-term efficacy and tolerability in these subjects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1533209","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:16:28Z","timestamp":1739164588000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Elisa","family":"Dinoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia","family":"Baldinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Campi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dardano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","article-title":"Prader\u2013willi syndrome","volume":"14","author":"Cassidy","year":"2012","journal-title":"Genet Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2018-105301","article-title":"Molecular genetic classification in Prader\u2013Willi syndrome: a multisite cohort study","volume":"56","author":"Butler","year":"2019","journal-title":"J Med Genet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00002-4","article-title":"Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction","volume":"9","author":"Tauber","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01574-9","article-title":"Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches","volume":"44","author":"Muscogiuri","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-023-02633-5","article-title":"The Italian registry for patients with Prader-Willi syndrome","volume":"18","author":"Salvatore","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-020-1284-5","article-title":"Update on diabetes mellitus and glucose metabolism alterations in prader-willi syndrome","volume":"20","author":"Crin\u00f2","year":"2020","journal-title":"Curr Diabetes Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0038","article-title":"Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome","volume":"96","author":"Sze","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03280.x","article-title":"Liraglutide therapy in Prader-Willi syndrome","volume":"28","author":"Cyganek","year":"2011","journal-title":"Diabetes Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/pdi.1621","article-title":"Successful treatment of obesity and diabetes with incretin analogue over four years in an adult with Prader\u2013Willi syndrome","volume":"28","author":"Paisey","year":"2011","journal-title":"Pract Diabetes"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2010.12.009","article-title":"Treating diabetes mellitus in Prader-Willi syndrome with Exenatide","volume":"92","author":"Seetho","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej12-0074","article-title":"The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome","volume":"59","author":"Senda","year":"2012","journal-title":"Endocr J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2575","article-title":"Use of GLP-1 receptor agonists in Prader-Willi Syndrome: report of six cases","volume":"37","author":"Fintini","year":"2014","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12131","article-title":"Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome","volume":"12","author":"Salehi","year":"2017","journal-title":"Pediatr Obes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0369-5","article-title":"Effectiveness of sodium-glucose cotransporter-2 inhibitor as an add-on drug to GLP-1 receptor agonists for glycemic control of a patient with prader-willi syndrome: A case report","volume":"9","author":"Horikawa","year":"2018","journal-title":"Diabetes Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2020.25.1.52","article-title":"Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome","volume":"25","author":"Kim","year":"2020","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.29.81","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report","volume":"29","author":"Sano","year":"2020","journal-title":"Clin Pediatr Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2019-0389","article-title":"Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report","volume":"33","author":"Candler","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35102","article-title":"Weight loss of over 100 lbs in a patient of prader-willi syndrome treated with glucagon-like peptide-1 (GLP-1) agonists","volume":"15","author":"Ahmed","year":"2023","journal-title":"Cureus"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2174\/1871530322666220509225637","article-title":"Effects of semaglutide on glycemic control and weight loss in a patient with prader-willi syndrome: A case report","volume":"22","author":"Sani","year":"2022","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2023.12.001","article-title":"Effect of semaglutide on weight loss and glycaemic control in patients with Prader-Willi Syndrome and type 2 diabetes","volume":"71","author":"Gim\u00e9nez-Palop","year":"2024","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S141352","article-title":"Obesity management in Prader-Willi syndrome: current perspectives","volume":"11","author":"Crin\u00f2","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14583","article-title":"The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review","volume":"96","author":"Ng","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/clinem\/dgac549","article-title":"Liraglutide for weight management in children and adolescents with prader-willi syndrome and obesity","volume":"108","author":"Diene","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0566","article-title":"Management Of Endocrine Disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa240334","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1533209\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:16:31Z","timestamp":1739164591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1533209\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":28,"alternative-id":["10.3389\/fendo.2025.1533209"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1533209","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"article-number":"1533209"}}